Filing Flows › Recursion Pharmaceuticals (RXRX) › Guidance & outlook
Recursion Pharmaceuticals (RXRX) guidance and outlook
Recursion Pharmaceuticals' 10-Q filed Nov 2, 2026 makes 8 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 2, 2026
- The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year.
- We anticipate that we will need to raise additional financing in the future to fund our operations, including the potential commercialization of any approved product candidates.
- Until such time, if ever, as we can generate significant product revenue, we expect to finance our operations with our existing cash and cash equivalents, any future equity or debt financings and upfront, milestone and royalty payments, if any, received under current or future license or collaboration agreements.
- We intend to continue maintaining a full valuation allowance on the Canadian DTAs until there is sufficient evidence to support the reversal of all or some portion of these allowances.
- However, given our current earnings and anticipated future earnings of our Canadian operations, we believe that there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to allow us to reach a conclusion that a significant portion of the valuation allowance will no longer be needed.
- For the three and nine months ended September 30, 2026, the change in cost of revenue compared to the prior period was due to a decrease in costs of revenue recognized from Roche, which was due to the shifting scope of work across our various performance obligations as certain phases of the projects reached completion.
- We have not yet commercialized any products and do not expect to generate revenue from the sales of any product candidates for at least several years.
- We have incurred operating losses and experienced negative operating cash flows and we anticipate that the Company will continue to incur losses for at least the foreseeable future.
Recursion Pharmaceuticals' latest quarter
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Questions
What does Recursion Pharmaceuticals expect?
The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year. We anticipate that we will need to raise additional financing in the future to fund our operations, including the potential commercialization of any approved product candidates. Until such time, if ever, as we can generate significant product revenue, we expect to finance our operations with our existing cash and cash equivalents, any future equity or debt financings and upfront, milestone and royalty payments, if any, recei
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.